4599.T
StemRIM [4599.T] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
4599.T Stock Summary
Top 10 Correlated ETFs
4599.T
Top 10 Correlated Stocks
4599.T
In the News
4599.T Financial details
Company Rating
-
Market Cap
28.03B
Income
179.4M
Revenue
2.35B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
45
Optionable
No
Shortable
Yes
Earnings
12 Jun 2024
P/E
158.46
Forward P/E
-
PEG
-14.35
P/S
14.59
P/B
3.41
P/C
-
P/FCF
60.57
Quick Ratio
83.62
Current Ratio
84
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
3.42
EPS next Y
-
EPS next Q
-
EPS this Y
-108.51%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
88.02%
Revenue Q/Q
-
EPS Q/Q
14.75%
-
-
-
-
SMA20
-18.34%
SMA50
-13.75%
SMA100
-22.91%
Inst Own
-
Inst Trans
-
ROA
2%
ROE
2%
ROC
0.02%
Gross Margin
100%
Oper. Margin
7%
Profit Margin
9%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
444.0-1429.0
52W High
-79.71%
52W Low
-34.68%
RSI
43
Rel Volume
0.84
Avg Volume
288.2K
Volume
242.5K
Perf Week
7.01%
Perf Month
-15.45%
Perf Quarter
-20.77%
Perf Half Y
-19.44%
-
-
-
-
Beta
1.433
-
-
Volatility
11.36%, 29.7%
Prev Close
3.2%
Price
290
Change
0%
Company Profile
- Volume Average 288.2K
- Market Capitalization 28.03B
- Employee 45
- CEO Mr. Masatsune Okajima
- Headquarters Ibaraki,JP
- IPO Date 2019-08-09
-
Website
https://www.stemrim.com 
StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy; PJ2, a regeneration-inducing medicine novel peptides A and B; PJ3, a biologic regeneration-inducing protein; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.
